PubMed Health⌕ Search

Biomedical subjects

Michael Barnes

Publications and source records attributed to Michael Barnes.

3 recordsLinked to original sources

Open Source software in medical informatics--why, how and what.

'Open Source' is a 20-40 year old approach to licensing and distributing software that has recently burst into public view. Against conventional wisdom this approach has been wildly successful in the general software market--probably because the openness lets programmers the world over obtain, critique, use, and build upon the source code without licensing fees. Linux, a UNIX-like operating system, is the best known success. But computer scientists at the University of California, Berkeley began the tradition of software sharing in the mid 1970s with BSD UNIX and distributed the major internet network protocols as source code without a fee. Medical informatics has its own history of Open Source distribution: Massachusetts General's COSTAR and the Veterans Administration's VISTA software have been distributed as source code at no cost for decades. Bioinformatics, our sister field, has embraced the Open Source movement and developed rich libraries of open-source software. Open Source has now gained a tiny foothold in health care (OSCAR GEHR, OpenEMed). Medical informatics researchers and funding agencies should support and nurture this movement. In a world where open-source modules were integrated into operational health care systems, informatics researchers would have real world niches into which they could engraft and test their software inventions. This could produce a burst of innovation that would help solve the many problems of the health care system. We at the Regenstrief Institute are doing our part by moving all of our development to the open-source model.

Database Management Systems↗

Botulinum toxin--mechanisms of action and clinical use in spasticity.

Botulinum toxin is a potent neurotoxin produced by the bacterium Clostridium botulinum. There are seven serotypes, all of which block the release of acetylcholine from nerve endings, which gives the compound its theoretical base for reducing spasticity. Initial studies of the use of botulinum toxin in the management of spasticity were promising and now there are a number of well-designed, double-blind, placebo-controlled studies that confirm the place of botulinum toxin in our treatment armoury against focal spasticity. The studies have demonstrated both efficacy and safety. There is still more work to be done in terms of disability although early reports confirm functional improvements, particularly reduction of pain as well as improvements in nursing care, hygiene and carer burden. Further studies also need to be done to confirm the place of botulinum toxin in the overall context of other treatment possibilities in the management of spasticity.

Adult↗

Life expectancy determination.

The estimate of life expectancy following a personal injury is probably one of the most important factors in determining the final quantum of damages. It is a calculation fraught with difficulties. This article endeavours to outline some general factors that aid prediction of life expectancy, and also discusses the evidence from the few long-term studies currently available.

Chronic Disease↗